Troglitazone improves cardiac function in patients with congestive heart failure.
Troglitazone increased cardiac output and stroke volume, as a result of decreased peripheral resistance, in diabetic patients with normal cardiac function. The cardiovascular effects of troglitazone in patients with heart failure are unknown. The aim of the study was to evaluate the cardiovascular effects of troglitazone in patients with heart failure. Blood pressure and echocardiographic findings were evaluated before and 1, 2, 3 and 4 hours after a single dose of troglitazone (400 mg) or placebo, in eight type II diabetic patients with congestive heart failure. The plasma catecholamines and coefficient of variance of RR intervals (CVRR) were also measured. Neither heart rate nor blood pressure changed after the administration of troglitazone. Left ventricular (LV) end-diastolic dimension did not change either, however, the LV end-systolic dimension significantly decreased compared with its baseline value and with that of the placebo group. On the other hand, the % fractional shortening and the E/A ratio increased significantly after troglitazone. The LV end-diastolic volume did not change, whereas the LV end-systolic volume significantly decreased. The stroke volume and the LV ejection fraction significantly increased compared with its baseline value and with that of the placebo group. The peripheral vascular resistance did not change after the administration of troglitazone, whereas plasma catecholamines significantly decreased, and CVRR remained unchanged in both groups. These hemodynamic changes suggest that a single oral dose of troglitazone induced inotropy without activation of the sympathetic nervous system.
Ogino
Kazuhide
K
Division of Cardiology, Department of Medicine, Faculty of Medicine, Tottori University, 36-1 Nishimachi, Yonago 683-8504, Japan. k-ogino@umin.ac.jp
Furuse
Yoshiyuki
Y
Uchida
Kazuhiko
K
Shimoyama
Masaki
M
Kinugawa
Toru
T
Osaki
Shuichi
S
Kato
Masahiko
M
Endo
Akihiro
A
Igawa
Osamu
O
Hisatome
Ichiro
I
Ikawa
Shiro
S
Shigemasa
Chiaki
C
D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D002395:Catecholamines / Q000097:blood; D002839:Chromans / Q000097:blood / Q000627:therapeutic use*; D018592:Cross-Over Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D013318:Stroke Volume / Q000187:drug effects; D013844:Thiazoles / Q000097:blood / Q000627:therapeutic use*; D045162:Thiazolidinediones; D013997:Time Factors; D000077288:Troglitazone; D014665:Vasodilator Agents / Q000097:blood / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects
D002395:Catecholamines; D002839:Chromans; D013844:Thiazoles; D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077288:Troglitazone